Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Glenmark will begin distribution in November 2025
_256_384.jpg)
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Subscribe To Our Newsletter & Stay Updated
